ES 285

Drug Profile

ES 285

Alternative Names: ES-285

Latest Information Update: 13 Nov 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaMar
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Cytoskeletal protein inhibitors; Glucosylceramide synthase inhibitors; Rho GTP-binding protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 Oct 2008 Efficacy & adverse events data from three phase I trials in Solid tumours presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
  • 31 Dec 2007 Discontinued - Phase-I for Solid tumours in Spain (IV)
  • 31 Dec 2007 Discontinued - Phase-I for Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top